CoChat

The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab

Open access
Scartozzi, Mario, Mandolesi, Alessandra, Giampieri, Riccardo, Bittoni, Alessandro, Pierantoni, Chiara, Zaniboni, Alberto, Galizia, Eva, Giustini, Lucio, Silva, Rosa Rita, Bisonni, Renato, Berardi, Rossana, Biscotti, Tommasina, Biagetti, Simona, Bearzi, Italo, Cascinu, Stefano · 2011 · The Oncologist
Cited by 63

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Learning Objectives: After completing this course, the reader will be able to: Describe the relationship between HER-3 status and response to treatment with cetuximab and irinotecan in patients with advanced colorectal cancer and EGFR+ wild-type K-RAS mutation in this study.Evaluate data that support using HER-3 status as a predictive factor for anti-EGFR treatment response in patients with colorectal cancer. CME This article is available for continuing medical education credit at CME.TheOncologist.com Preclinical data suggested that, in the presence of human epidermal growth factor receptor (HER)-3–altered activation, colorectal cancer cells may escape anti–epidermal growth factor receptor (EGFR)-mediated cell death. HER-3 overexpression may then represent a key factor for resistance to anti-EGFR antibodies in colorectal cancer. The aim of our analysis was to investigate a possible correlation between HER-3 expression and clinical outcome in wild-type K-RAS advanced colorectal cancer patients receiving cetuximab and irinotecan. We retrospectively analyzed immunoreactivity for HER-3 in wild-type K-RAS advanced colorectal cancer patients receiving irinotecan and cetuximab. Eighty-four advanced wild-type K-RAS colorectal cancer patients were available for HER-3 analysis. Forty patients (48%) had a HER-3− colorectal tumor, whereas the remaining 44 cases (52%) were deemed HER-3+. In patients with HER-3− and HER-3+ tumors, we observed a partial response in 17 (42%) and eight (18%) patients respectively; progressive disease occurred in 11 (35%) and 26 (53%) patients with HER-3− and HER-3+ tumors, respectively (p = .003). The median progression-free survival time was 6.3 months in patients with HER-3− tumors and 2.8 months for those who had HER-3–overexpressing tumors (p < .0001). The median overall survival time was 13.6 months in patients showing HER-3− tumors and 10.5 months for those who had HER-3–expressing tumors (p = .01). HER-3 proved to be a predictive factor for clinical outcome in wild-type K-RAS colorectal cancer patients treated with cetuximab. Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2010-0119

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 63

Metadata

Authors
Scartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., Berardi, R., Biscotti, T., Biagetti, S., Bearzi, I., & Cascinu, S.
Venue
The Oncologist
Published
2011-01-01
Volume
16
Issue
1
Pages
53-60
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2103129141
Cited by
63
References
9
FWCI
3.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. https://app.cochat.ai/papers/10.1634/theoncologist.2010-0119
The paper
Scartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., Berardi, R., Biscotti, T., Biagetti, S., Bearzi, I., & Cascinu, S. (2011). The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. The Oncologist. https://doi.org/10.1634/theoncologist.2010-0119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.